Cardlytics (CDLX) EBITDA (2017 - 2026)

Cardlytics (CDLX) has reported EBITDA for 10 consecutive years, with -$5.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 43.14% year-over-year to -$5.4 million; the trailing twelve-month figure through Jun 2026 stood at -$88.7 million (up 50.06% YoY), and the FY2025 full-year result was -$101.8 million, up 47.92% from the prior year.
• EBITDA advanced to -$5.4 million in Q2 2026 per CDLX's latest filing, from -$8.3 million in the prior quarter.
• Across five years, EBITDA topped out at $35.7 million in Q1 2022 and bottomed at -$382.6 million in Q4 2022.
• Historically, EBITDA has averaged -$49.9 million across 5 years, with a median of -$13.5 million in 2024.
• The widest YoY moves for EBITDA: up 260.84% in 2022, down 2231.86% in 2022.
• Over 5 years, EBITDA stood at -$382.6 million in 2022, then soared by 73.1% to -$102.9 million in 2023, then surged by 91.92% to -$8.3 million in 2024, then rose by 26.69% to -$6.1 million in 2025, then climbed by 10.73% to -$5.4 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$5.4 million, -$8.3 million, and -$6.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.